CLINICAL RESEARCH: CLINICAL TRIAL
Maintenance of sinus rhythm in patients with atrial fibrillation
An AFFIRM substudy of the first antiarrhythmic drug
The AFFIRM First Antiarrhythmic Drug Substudy Investigators*
Manuscript received November 1, 2002;
revised manuscript received January 3, 2003,
accepted January 24, 2003.
* Reprint requests and correspondence: Dr. H. Leon Greene, AFFIRM Clinical Trial Center, Axio Research Corporation, 2601 Fourth Avenue, Suite 200, Seattle, Washington 98121, USA
leong{at}axioresearch.com
OBJECTIVES: This study evaluated the efficacy of antiarrhythmic drugs for the treatment of atrial fibrillation (AF).
BACKGROUND: The most effective and safest antiarrhythmic drug for the treatment of AF is unknown.
METHODS: The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study compared two treatment strategies—rate control and rhythm control—in patients with AF and risk factors for stroke or death. This substudy, performed in patients randomized to rhythm control, compared different antiarrhythmic drugs by randomly assigning the first drug treatment to: 1) amiodarone, 2) sotalol, or 3) a class I drug. The primary end point was the proportion of patients alive, in sinus rhythm, with no additional cardioversions and still taking the assigned drug at one year. Comparisons were made between patients eligible for each of three drug pairs.
RESULTS: At one year, in 222 patients randomized between amiodarone and class I agents, 62% were successfully treated with amiodarone, compared with 23% taking class I agents (p < 0.001). In 256 patients randomized between amiodarone and sotalol, 60% versus 38% were successfully treated, respectively (p = 0.002). In 183 patients randomized between sotalol and class I agents, 34% versus 23% were successfully treated, respectively (p = 0.488), although this portion of the substudy was stopped early when amiodarone was shown to be better than class I agents. Sinus rhythm was achieved in nearly 80% of patients at one-year follow-up with serial therapy. Adverse effects were common.
CONCLUSIONS: Amiodarone was more effective at one year than either sotalol or class I agents for the strategy of maintenance of sinus rhythm without cardioversion.
|
Abbreviations and Acronyms
| | AF | | atrial fibrillation | | AFFIRM | | Atrial Fibrillation Follow-up Investigation of Rhythm Management | | ECG | | electrocardiogram/electrocardiographic |
|
This article has been cited by other articles:
|
|
|
|
 
S. Saksena, A. Slee, A. L. Waldo, N. Freemantle, M. Reynolds, Y. Rosenberg, S. Rathod, S. Grant, E. Thomas, and D. G. Wyse
Cardiovascular Outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management): An Assessment of Individual Antiarrhythmic Drug Therapies Compared With Rate Control With Propensity Score-Matched Analyses
J. Am. Coll. Cardiol.,
November 1, 2011;
58(19):
1975 - 1985.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Markowitz
Rhythm Control for Atrial Fibrillation: Favorable Outcomes or Futile Endeavor?
J. Am. Coll. Cardiol.,
November 1, 2011;
58(19):
1986 - 1988.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Camm, G. Breithardt, H. Crijns, P. Dorian, P. Kowey, J.-Y. Le Heuzey, I. Merioua, L. Pedrazzini, E. N. Prystowsky, P. J. Schwartz, et al.
Real-Life Observations of Clinical Outcomes With Rhythm- and Rate-Control Therapies for Atrial Fibrillation: RECORDAF (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation)
J. Am. Coll. Cardiol.,
July 26, 2011;
58(5):
493 - 501.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, G. N. Kay, J.-Y. Le Huezey, J. E. Lowe, et al.
2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
J. Am. Coll. Cardiol.,
March 15, 2011;
57(11):
e101 - e198.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, G. N. Kay, J.-Y. Le Huezey, J. E. Lowe, et al.
2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Circulation,
March 15, 2011;
123(10):
e269 - e367.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Freemantle, C. Lafuente-Lafuente, S. Mitchell, L. Eckert, and M. Reynolds
Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation
Europace,
March 1, 2011;
13(3):
329 - 345.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. de Bono, V. M. Stoll, A. Joshi, K. Rajappan, Y. Bashir, and T. R. Betts
Cavotricuspid isthmus dependent flutter is associated with an increased incidence of occult coronary artery disease
Europace,
December 1, 2010;
12(12):
1774 - 1777.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J. McLeod and B. J. Gersh
A practical approach to the management of patients with atrial fibrillation
Heart Asia,
September 6, 2010;
2(1):
95 - 103.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Lavalle, R. P. Ricci, and M. Santini
Atrial tachyarrhythmias and cardiac resynchronisation therapy: clinical and therapeutic implications
Heart,
August 1, 2010;
96(15):
1174 - 1178.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Finnin
Vernakalant: A novel agent for the termination of atrial fibrillation
Am. J. Health Syst. Pharm.,
July 15, 2010;
67(14):
1157 - 1164.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Wilber
Antiarrhythmic Drug Therapy vs Catheter Ablation for Paroxysmal Atrial Fibrillation--Reply
JAMA,
May 12, 2010;
303(18):
1809 - 1810.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Singh, E. Cingolani, G. A. Diamond, and S. Kaul
Dronedarone for Atrial Fibrillation: Have We Expanded the Antiarrhythmic Armamentarium?
J. Am. Coll. Cardiol.,
April 13, 2010;
55(15):
1569 - 1576.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J Schilling
Cardioversion of atrial fibrillation: the use of antiarrhythmic drugs
Heart,
March 1, 2010;
96(5):
333 - 338.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Wilber, C. Pappone, P. Neuzil, A. De Paola, F. Marchlinski, A. Natale, L. Macle, E. G. Daoud, H. Calkins, B. Hall, et al.
Comparison of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation: A Randomized Controlled Trial
JAMA,
January 27, 2010;
303(4):
333 - 340.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Schmidt, M. Daccarett, and J. Brachmann
Atrial fibrillation ablation in systolic heart failure patients: a promising tool?
Europace,
January 1, 2010;
12(1):
1 - 2.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Brodsky
Letter by Brodsky Regarding Article "Treatment of Atrial Fibrillation With Antiarrhythmic Drugs or Radiofrequency Ablation: Two Systematic Literature Reviews and Meta-Analyses"
Circ Arrhythm Electrophysiol,
December 1, 2009;
2(6):
e44 - e44.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Piccini, R. D. Lopes, M. H. Kong, V. Hasselblad, K. Jackson, and S. M. Al-Khatib
Pulmonary Vein Isolation for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation: A Meta-Analysis of Randomized, Controlled Trials
Circ Arrhythm Electrophysiol,
December 1, 2009;
2(6):
626 - 633.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Piccini, V. Hasselblad, E. D. Peterson, J. B. Washam, R. M. Califf, and D. F. Kong
Comparative Efficacy of Dronedarone and Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation
J. Am. Coll. Cardiol.,
September 15, 2009;
54(12):
1089 - 1095.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Reynolds, P. Zimetbaum, M. E. Josephson, E. Ellis, T. Danilov, and D. J. Cohen
Cost-Effectiveness of Radiofrequency Catheter Ablation Compared With Antiarrhythmic Drug Therapy for Paroxysmal Atrial Fibrillation
Circ Arrhythm Electrophysiol,
August 1, 2009;
2(4):
362 - 369.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. B. Forleo and C. Tondo
Atrial fibrillation: cure or treat?
Therapeutic Advances in Cardiovascular Disease,
June 1, 2009;
3(3):
187 - 196.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. P. Ricci, A. Quesada, J. Almendral, F. Arribas, C. Wolpert, P. Adragao, M. Zoni-Berisso, X. Navarro, T. DeSanto, A. Grammatico, et al.
Dual-chamber implantable cardioverter defibrillators reduce clinical adverse events related to atrial fibrillation when compared with single-chamber defibrillators: a subanalysis of the DATAS trial
Europace,
May 1, 2009;
11(5):
587 - 593.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Camm, P. Kirchhof, G. Y.H. Lip, I. Savelieva, and S. Ernst
CHAPTER 29 Atrial Fibrillation
ESC Textbook of Cardiovascular Medicine,
January 1, 2009;
2(1):
med-9780199566990-chapter - med-9780199566990-chapter.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. K. Voeller, R. B. Schuessler, and R. J. Damiano Jr.
Surgical Treatment of Atrial Fibrillation
Card. Surg. Adult,
January 1, 2008;
3(2008):
1375 - 1394.
[Full Text]
|
|
|
|
|
|
|
P. Vassallo and R. G. Trohman
Prescribing Amiodarone: An Evidence-Based Review of Clinical Indications
JAMA,
September 19, 2007;
298(11):
1312 - 1322.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Shantsila, T. Watson, and G. Y. Lip
Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias
Europace,
September 1, 2007;
9(suppl_4):
iv37 - iv44.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Essebag, M. R. Reynolds, T. Hadjis, R. Lemery, B. Olshansky, A. E. Buxton, M. E. Josephson, and P. Zimetbaum
Sex Differences in the Relationship Between Amiodarone Use and the Need for Permanent Pacing in Patients With Atrial Fibrillation
Arch Intern Med,
August 13, 2007;
167(15):
1648 - 1653.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Pappone, G. Augello, S. Sala, F. Gugliotta, G. Vicedomini, S. Gulletta, G. Paglino, P. Mazzone, N. Sora, I. Greiss, et al.
A Randomized Trial of Circumferential Pulmonary Vein Ablation Versus Antiarrhythmic Drug Therapy in Paroxysmal Atrial Fibrillation: The APAF Study
J. Am. Coll. Cardiol.,
December 5, 2006;
48(11):
2340 - 2347.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Writing Committee Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al.
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Europace,
September 1, 2006;
8(9):
651 - 745.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
J. Am. Coll. Cardiol.,
August 15, 2006;
48(4):
e149 - e246.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
Circulation,
August 15, 2006;
114(7):
e257 - e354.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. S. Chan, S. Vijan, F. Morady, and H. Oral
Cost-Effectiveness of Radiofrequency Catheter Ablation for Atrial Fibrillation
J. Am. Coll. Cardiol.,
June 20, 2006;
47(12):
2513 - 2520.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Lafuente-Lafuente, S. Mouly, M. A. Longas-Tejero, I. Mahe, and J.-F. Bergmann
Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials.
Arch Intern Med,
April 10, 2006;
166(7):
719 - 728.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Domanski
Prognosis in atrial fibrillation
Eur. Heart J.,
April 2, 2006;
27(8):
895 - 896.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Additional Information
JAMA,
November 2, 2005;
294(17):
E1 - E3.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Verma, A. Natale, B. J. Padanilam, E. N. Prystowsky, A. Verma, A. Natale, B. J. Padanilam, and E. N. Prystowsky
Why Atrial Fibrillation Ablation Should Be Considered First-Line Therapy for Some Patients
Circulation,
August 23, 2005;
112(8):
1214 - 1222.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Olshansky, E. N. Heller, L. B. Mitchell, M. Chandler, W. Slater, M. Green, M. Brodsky, P. Barrell, H. L. Greene, and and the AFFIRM Investigators
Are Transthoracic Echocardiographic Parameters Associated With Atrial Fibrillation Recurrence or Stroke?: Results From the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study
J. Am. Coll. Cardiol.,
June 21, 2005;
45(12):
2026 - 2033.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Zimetbaum
An Argument for Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation
Circulation,
June 14, 2005;
111(23):
3150 - 3156.
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. M. Wazni, N. F. Marrouche, D. O. Martin, A. Verma, M. Bhargava, W. Saliba, D. Bash, R. Schweikert, J. Brachmann, J. Gunther, et al.
Radiofrequency Ablation vs Antiarrhythmic Drugs as First-line Treatment of Symptomatic Atrial Fibrillation: A Randomized Trial
JAMA,
June 1, 2005;
293(21):
2634 - 2640.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M B. Iqbal, A. K Taneja, G. Y H Lip, and M. Flather
Recent developments in atrial fibrillation
BMJ,
January 29, 2005;
330(7485):
238 - 243.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Zimetbaum and M. E. Josephson
Is There a Role for Maintaining Sinus Rhythm in Patients with Atrial Fibrillation?
Ann Intern Med,
November 2, 2004;
141(9):
720 - 726.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Dorian, I. Mangat, A. Pinter, and V. Korley
The Burden of Atrial Fibrillation: Should We Abandon Antiarrhythmic Drug Therapy?
Journal of Cardiovascular Pharmacology and Therapeutics,
October 1, 2004;
9(4):
257 - 262.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. S. Steinberg, A. Sadaniantz, J. Kron, A. Krahn, D. M. Denny, J. Daubert, W. B. Campbell, E. Havranek, K. Murray, B. Olshansky, et al.
Analysis of Cause-Specific Mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study
Circulation,
April 27, 2004;
109(16):
1973 - 1980.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Olshansky, L. E. Rosenfeld, A. L. Warner, A. J. Solomon, G. O'Neill, A. Sharma, E. Platia, G. K. Feld, T. Akiyama, M. A. Brodsky, et al.
The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: Approaches to control rate in atrial fibrillation
J. Am. Coll. Cardiol.,
April 7, 2004;
43(7):
1201 - 1208.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.J. Boos, J. Carlsson, and R.S. More
Rate or rhythm control in persistent atrial fibrillation?
QJM,
December 1, 2003;
96(12):
881 - 892.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
